Why a medicine list belongs beside a gene result

A pharmacogenomic report may be years old while the medicine list beside it changes every month. Those two documents answer different questions. The DNA result describes an inherited finding. The current medicine list helps a professional assess the conditions under which a medicine is being used now.

One reason is phenoconversion: observed enzyme activity can differ from what a genetic result alone predicts. The 2023 CPIC serotonin-reuptake-inhibitor guideline discusses this in the context of enzyme inhibitors and inducers. The term does not mean that another medicine has rewritten someone’s DNA.

Two dates belong in the conversation

In a fictional example, Sam has a report printed in March and a prescription change recorded in September. Sam notices that the phenotype label on the report has not changed. That is expected: a report does not automatically update when the medicine list changes. What may need reassessment is its application to the current treatment situation.

Sam writes the report date and the date of the prescription change on the same page. No medicine is stopped or adjusted. The note simply helps a pharmacist see that the result and the medicine list describe different moments. It prevents the old report from being mistaken for a current interaction assessment.

That distinction is useful even when no relevant interaction is ultimately found. A timeline allows the professional to establish what was taken when a result, symptom or monitoring measurement occurred. A list with no dates can be much harder to interpret, especially when a short course or a recently discontinued product is missing from it.

A prediction is not a live measurement

A genotype-derived phenotype is a translation using a particular framework. It is not a continuous readout of enzyme activity in the person’s body. Reading the word “normal” as a promise that all medicines will behave normally adds a claim the report cannot carry.

The NCBI Medical Genetics Summary for propafenone and CYP2D6 provides another medicine-specific discussion of this context. Its purpose here is to illustrate why an inherited result and current drug effects need to be considered together. It does not make every CYP2D6-related medicine interchangeable, and it cannot determine whether an unnamed person has phenoconversion.

The strength and timing of a drug effect matter. A reader should therefore resist turning an online list into a simple on/off label. “This product appears on an inhibitor list” is a reason to ask a specific question, not enough information to decide what should happen to treatment.

An interaction table has its own purpose

The FDA publishes tables of substrates, inhibitors and inducers. These tables support drug-development and interaction work. They are not an exhaustive patient-specific interaction checker.

That boundary matters when a search returns a familiar product name. The presence of a name can be relevant; its absence cannot certify that a combination is safe. The table may also use a medicine for a particular research purpose rather than offer instructions for a patient taking it. Keep the source’s intended use attached to any information copied from it.

For a useful medication review, record the actual product name rather than a vague category such as “an antidepressant” or “a supplement”. Include over-the-counter products and short courses when the pharmacist asks for them. If you cannot remember the name, mark it unknown and bring the packaging or dispensing record. An honest gap is preferable to a confidently guessed ingredient.

A question that travels well

Try this wording: “This is the laboratory’s predicted phenotype. Does my current medicine list affect how it should be used for this particular drug?” It separates the result from the professional assessment and keeps the question tied to a named treatment.

You can add who will record the answer and whether a later prescription change should prompt another review. That is a practical follow-up arrangement, not a request for permanent monitoring by a report or an app. A saved document cannot know about a medicine that has never been entered into it.

The report is still useful. Its value is easier to preserve when it sits beside a current, dated medicine list rather than being treated as a self-updating instruction. Keep the inherited finding, the current context and the professional decision as separate records. None needs to be rewritten to make the others fit.

Scope and source access

Research accessed 4 October 2026: selected sections of the accessible CPIC guideline PDF, the NCBI summary PDF and the FDA table page. These sources address particular mechanisms and contexts, not every possible combination. This article offers no interaction verdict, diagnosis or medication change.